Collegamenti rapidi
Link per i membri
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
PPTA Announces Changes to Global Executive Board and European Board Leadership
PPTA Announces Changes to Global Executive Board and European Board Leadership
Categorie
Raccolta e lavorazione del plasma
Scopri di più sulla raccolta del plasma e trova i centri certificati per la raccolta del plasma più vicini a te.
Schede informative
Le schede informative forniscono ulteriori informazioni sull'industria terapeutica globale delle proteine plasmatiche.
Risorse per i pazienti
Esplora le risorse del PPTA per i pazienti interessati alle terapie a base di proteine plasmatiche.
Domande frequenti sul plasma
Ottieni risposte sulle terapie a base di plasma e sui processi di donazione e raccolta.
Sensibilizzazione
Scopri di più sulle iniziative di sensibilizzazione dell'Associazione per garantire ai pazienti l'accesso alle terapie.
Accesso alle cure
Consulta il registro completo dei problemi di accesso alle cure per regione e le attività del PPTA a sostegno dell'accesso alle terapie.
Rivista The Source
Iscriviti alla rivista internazionale dell'industria terapeutica delle proteine plasmatiche,
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Nov 10, 2026
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
All
PPTA Statements
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6af3642bc58c382cacfcdb31_PPTA_2680%20Cost%20Containment%20Position%20PaperV2.pdf
Nov 10, 2026
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
All
PPTA Statements
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6af3642bc58c382cacfcdb31_PPTA_2680%20Cost%20Containment%20Position%20PaperV2.pdf
Nov 10, 2026
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
All
Publication
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6af3642bc58c382cacfcdb31_PPTA_2680%20Cost%20Containment%20Position%20PaperV2.pdf
Nov 10, 2026
Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment
All
Publication
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6af3642bc58c382cacfcdb31_PPTA_2680%20Cost%20Containment%20Position%20PaperV2.pdf
Oct 28, 2026
Maintaining Immunoglobulins on the Union List of Critical Medicines to Safeguard Patient Access
As the review of the Union List of Critical Medicines (ULCM) approaches its conclusion, the Plasma Protein Therapeutics Association (PPTA) strongly supports maintaining human normal immunoglobulins (IG) on the Union list1 as they are lifesaving, irreplaceable treatments of human origin facing ongoing supply challenges. Maintaining IG on the Union list supports the EU’s broader agenda to strengthen the resilience, security and sustainability of medicines supply as well as safeguard reliable access for patients across Europe.
All
PPTA Statements
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6ae22ea3cac65bcf56c49109_FINAL%20PPTA%20statement%20on%20Union%20List%20of%20Critical%20Medicines_28.10.2026.pdf
Oct 28, 2026
Maintaining Immunoglobulins on the Union List of Critical Medicines to Safeguard Patient Access
As the review of the Union List of Critical Medicines (ULCM) approaches its conclusion, the Plasma Protein Therapeutics Association (PPTA) strongly supports maintaining human normal immunoglobulins (IG) on the Union list1 as they are lifesaving, irreplaceable treatments of human origin facing ongoing supply challenges. Maintaining IG on the Union list supports the EU’s broader agenda to strengthen the resilience, security and sustainability of medicines supply as well as safeguard reliable access for patients across Europe.
All
PPTA Statements
https://cdn.prod.website-files.com/6916f1777886bb3b9377a752/6ae22ea3cac65bcf56c49109_FINAL%20PPTA%20statement%20on%20Union%20List%20of%20Critical%20Medicines_28.10.2026.pdf
No results found